4528Ono Pharmaceutical Co., Ltd.

🇯🇵 Japonya Borsası
2499.00
JPY
Analysis Scores
Lothien Robustness Score?
80/100
Very Strong
Neden bu skor?
Damodaran ?
64/100
Dalio Risk ?
94/100
Piotroski ?
3/9
Weak
Previous period ROA data missing (C1 delta-ROA); Total assets data missing → ROA cannot be calculated (C2); Önceki yıl borç/varlık verisi yok → kaldıraç azalması kontrol edilemedi (C5); Current ratio data missing (C6); current assets data missing → turnover calculation unavailable (C9)
Graham ?
Veri Yetersiz
Özkaynaklar negatif veya sıfır — Graham formülü pozitif defter değeri gerektirir
Active Metric?
4/4
Confidence?
75%
Lothien Robustness Summary
72/100
Lothien Sağlamlık: Güçlü (72/100)
Genel tablo olumlu. Finansal yapı sağlam, bazı riskler mevcut. | Kısa Vade: Olumlu | Uzun Vade: Nötr | Pozitif: 4 | Negatif: 0 | Nötr: 0
Net Kâr Pozitif
Son çeyrekte ¥24.2B net kâr açıklandı. Şirket kârlı.
Çeyreklik Kâr Artışı
Net kâr bir önceki çeyreğe göre %+39.1 arttı (¥17.4B → ¥24.2B). Kısa vadede olumlu momentum.
Yıllık Kâr Büyümesi Güçlü
Geçen yılın aynı dönemine göre net kâr %+36.7 arttı. Büyüme trendi sağlıklı.
Lothien Sağlamlık Skoru: 80/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı güçlü görünüyor.

Data date 2026-10-23 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-10-23
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Orta
252 days
Annual Volatility ?
%26.2
VaR 95% ?
%2.56
daily max loss
VaR 99% ?
%3.68
daily max loss
CVaR 95% ?
%3.27
expected loss (tail)
Max Drawdown ?
%19.3
27.02.2026 → 03.06.2026
Skewness ?
0.25
Parametrik%2.56
Historik%2.52
Cornish-Fisher%2.39
Return Distribution
Valuation
Potential?
+48.0%
ROIC ?
8.6%
DCF Value ?
6,164.32
Debt Cycle?
Early Expansion
Balance Sheet Analysis? Q2026/6
Net kâr çeyreklik %+39.1 artarak 24.2B JPY oldu
Yıllık net kâr büyümesi %+36.7
Ödenmiş sermaye: 469.9M JPY
Son 8 çeyrek ardışık kâr
Fiyat TRAMA-99 üzerinde: %+5.1 — teknik trend olumlu
Destek seviyesi: TRAMA-99 = 2376.79 JPY
Fundamental & Technical Analysis
Profitability
ROE - Return on Equity (TTM) %9.0
ROE %9.0 — low return on equity.
Free Cash Flow Margin (TTM) %16.0
TTM Free Cash Flow is %16.0'i. Strong FCF generation — profit quality is high.
Valuation
P/E Ratio 15.5x Sector: 20.8x
F/K 15.5x — sector median (20.8x) near reasonable levels.
P/B Ratio 1.39x Sector: 2.35x
PD/DD 1.39x — sector median's (2.35x) well below. Cheap relative to book value.
EV/EBITDA 8.6x Sector: 9.5x
EV/EBITDA 8.6x — sector median (9.5x) in line.
Indebtedness
Current Ratio 2.86x
Current ratio 2.86x — current assets are 2x short-term liabilities. Very healthy liquidity.
Net Debt / EBITDA 1.0x
Net Debt/EBITDA 1.0x — very low debt burden. Company can repay debt quickly.
Debt / Equity 0.14x
Low leverage — majority of assets financed by equity.
Interest Coverage 62.6x
Interest coverage 62.6x — very wide margin for paying interest expenses.
Growth
Revenue Growth (YoY) %+5.9
Revenue YoY %5.9 grew — positive but slow growth.
Net Profit Growth (YoY) %+36.7
Net profit YoY %36.7 increased — strong profit growth.
Seasonality Analysis Q1 (Oca-Mar)
Historically strongest quarter: Q1 (Jan-Mar) (avg. profit 20.6B). Weakest quarter: Q4 (Oct-Dec) (avg. profit 14.9B).
Score Explanations
Lothien Robustness
80/100
Very strong robustness score (80/100). Damodaran valuation, Dalio risk analysis and balance sheet quality criteria are largely met.
Very Strong
Potential
+48.0%
Plus %48.0 expected value (3725.72) vs current price comparison. 4/4 valuation models could be calculated. Model confidence %75.
Components: PE target: 3708.90 | P/B target: 4370.09 | EV/EBITDA target: 2762.93 | DCF target: 6164.32
Damodaran Valuation
64/100
Moderate Damodaran score (64/100). ROIC (%8.6) – WACC (%6.8) difference +1.9 bps. Value creation capacity limited.
Moderate
Dalio Risk Analysis
94/100
Low debt risk (94/100). Interest coverage ratio 62.6x — strong. Debt/EBITDA 1.0x — in healthy range.
Leverage: 87/100 | Debt Service: 100/100 | Quality: 86/100
ROIC - Return on Capital
%8.6
ROIC (%8.6) slightly exceeds cost of capital (1.9 points).
WACC: %6.8
DCF Discounted Cash Flow
6,164.32
DCF modeli 6164.32 target value produced — compared to current price %145.0 undervalued.
Current price: 2516.50
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
3/9
Weak Piotroski (3/9). Many balance sheet quality criteria not met. Note: Previous period ROA data missing (C1 delta-ROA); Total assets data missing → ROA cannot be calculated (C2)
Weak
Graham Intrinsic Value
—
⚖️ Sector Comparison
P/E Ratio
15.5x vs 20.8x
Sector median's %25 below — cheap
P/B Ratio
1.39x vs 2.35x
Compared to sector %41 cheaper (by book value)
EV/EBITDA
8.6x vs 9.5x
Compared to sector %9 lower EV/EBITDA
ROIC vs WACC
%8.6 vs %6.8 WACC
ROIC 1.9 bps above cost of capital
Net Profit Margin (TTM)
%12.7 vs %24.3 EBITDA margin
TTM net profit margin %12.7
TRAMA-99 Trend — Uptrend
Price (2499.00), TRAMA-99 line's %5.1 above. Uptrend ongoing; monitor for TRAMA approach for trend change.
Price:: 2499.00
TRAMA: 2376.79
Difference: %+5.1
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
P/E Ratio ?
P/B Ratio ?
EBITDA ?
Net Working Capital ?
Current Ratio ?
4528 — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.